When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BPMC - Blueprint Medicines' avapritinib continues to shows effect in mastocytosis study
Blueprint Medicines Corporation
Blueprint Medicines (NASDAQ:BPMC) announces updated data from part 1 of a Phase 2 clinical trial, PIONEER, evaluating Ayvakit (avapritinib) in patients with indolent (slow-growing) systemic mastocytosis. The results were virtually presented at the European Academy of Allergy and Clinical Immunology Congress (EAACI).
More news on: Blueprint Medicines Corporation, Healthcare stocks news,